163 related articles for article (PubMed ID: 19091259)
1. [Viral clearance in wild-type hepatitis B virus after treatment with pegylated interferon alpha-2a].
López López MP; Rincón Fuentes JP; Rabell Iñigo S; González Pérez-Crespo C; Rodríguez Gil FJ; Jorge Vidal V; Morán Sánchez S; Nicolás Del Prado MI
Gastroenterol Hepatol; 2008 Nov; 31(9):625-6. PubMed ID: 19091259
[No Abstract] [Full Text] [Related]
2. Idiopathic hepatitis B surface antibody seroreversion after pegylated interferon alpha-2a therapy.
Tsynman DN; Rivera R; Maliakkal B
J Gastrointestin Liver Dis; 2013 Mar; 22(1):110-1. PubMed ID: 23539403
[No Abstract] [Full Text] [Related]
3. Treatment of hepatitis B with interferon and combination therapy.
Cooksley WG
Clin Liver Dis; 2004 May; 8(2):353-70. PubMed ID: 15481344
[TBL] [Abstract][Full Text] [Related]
4. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a.
Chen J; Wang Z; Guo Y; Peng J; Sun J; Ahmed CS; Zhou Y; Hou J
Antiviral Res; 2009 Jan; 81(1):88-91. PubMed ID: 18948141
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report.
Yang J; Zhao LS
Virol J; 2009 Jul; 6():97. PubMed ID: 19583877
[TBL] [Abstract][Full Text] [Related]
6. Response predictors to treatment with pegylated interferon in chronic hepatitis B.
Ferreira PR; Tenore Sde B
Braz J Infect Dis; 2010; 14(5):519-25. PubMed ID: 21221484
[TBL] [Abstract][Full Text] [Related]
7. Early virologic response to pegylated interferon in chronic hepatitis B infection.
Ladep NG; Ugiagbe RA; Okonkwo U; Okeke EN; Malu AO
Niger J Med; 2009; 18(3):330-1. PubMed ID: 20120656
[TBL] [Abstract][Full Text] [Related]
8. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of add-on pegylated interferon alfa-2a therapy in a lamivudine-treated patient with chronic hepatitis B.
Mangano C; Squadrito G; Cacciola I; Carpentieri M; Foti G; Raimondo G
Ann Hepatol; 2011; 10(1):84-7. PubMed ID: 21301016
[TBL] [Abstract][Full Text] [Related]
10. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
11. Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment.
Jinato T; Chuaypen N; Poomipak W; Praianantathavorn K; Makkoch J; Kiatbumrung R; Jampoka K; Tangkijvanich P; Payungporn S
Exp Biol Med (Maywood); 2016 Oct; 241(16):1803-10. PubMed ID: 27190255
[TBL] [Abstract][Full Text] [Related]
12. [Quantification of hepatitis B virus HBsAg: clinical implications].
Buti M; Rodríguez Frías F; Esteban R
Med Clin (Barc); 2012 Apr; 138(11):483-8. PubMed ID: 21719049
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
14. The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon.
Cooksley G
J Hepatol; 2003; 39 Suppl 1():S143-5. PubMed ID: 14708693
[No Abstract] [Full Text] [Related]
15. Hepatitis B virus surface antigen seroconversion after pegylated interferon-alpha treatment in an HIV-infected individual with chronic hepatitis B.
Rossetti B; Bianco C; De Luca A
Infection; 2012 Jun; 40(3):347-9. PubMed ID: 22002731
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
[TBL] [Abstract][Full Text] [Related]
17. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
[TBL] [Abstract][Full Text] [Related]
18. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
Hui CK; Lai LS; Lam P; Zhang HY; Fung TT; Lai ST; Wong WM; Lo CM; Fan ST; Leung N; Lau GK;
Aliment Pharmacol Ther; 2006 Apr; 23(8):1171-8. PubMed ID: 16611278
[TBL] [Abstract][Full Text] [Related]
19. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
[TBL] [Abstract][Full Text] [Related]
20. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
Dogan UB; Golge N; Akin MS
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
